VISHAKHA BHAVE, BS (PHARMACY), PHD
Department of Pharmaceutical Sciences
Assistant Professor


Vishakha Bhave, BS (Pharmacy), PhD

Contact

Email: vishakhabh@pcom.edu
Office: 678-407-7363
Research Page

Dr. Bhave feels that the effectiveness of the material taught determines the success of a teacher. Her efforts as a teacher are directed towards making the subject matter interesting and relevant to the students. She hopes that the students can apply what they learn here for the betterment for their careers. Her primary teaching interests lie in the area of Pharmacology and Toxicology.

Additionally, Dr. Bhave also has an active research program that offers hand on research training experience to PharmD students. Her lab currently engages two third year and one second year PharmD students.

  • Education

    Post-doctoral fellowship: University of Pittsburgh School of Medicine, 2013
    PhD, University of Louisiana at Monroe, 2007
    Baccalaureate in Pharmacy: Mumbai University, 2002

  • Courses

    Immunology and microbiology
    Infectious Diseases I
    Toxicology

  • Research

    Research in Dr. Bhave’s lab focuses on investigating the mechanisms of liver regeneration and transdifferentiation.

    Project 1: Investigating the role of reprogramming factors (specifically OCT4), in transdifferentiation of hepatocytes to biliary epithelial cells. Clinical relevance is to find new therapeutic targets for chronic biliary liver diseases.

    Project 2: Investigate the role of protease and phospholipase inhibitors in treatment of drug-induced acute liver failure.

    Research Grants

    Ongoing Research Support

    1. American Association of Colleges of Pharmacy New Investigator Award

    Funding period: 01/2015- 12/2015
    Grant Title: Transdifferentiation: A New Approach for Biliary Diseases
    Role: PI
    Award amount: $10,000

    2. Center for Chronic Diseases of Aging (CCDA) grant

    Funding period: 07/2014- 06/2015
    Grant Title: Role of FXR- signaling in hepatocyte to biliary transdifferentiation.
    Role: PI
    Award amount: $9,300

    3. PCOM CSO funding

    Funding period: 07/2013- 06/2014
    Grant Title: Role of reprogramming factors in hepatocyte to biliary transdifferentiation.
    Role: PI
    Award amount: $13,000

    4. PCOM CSO funding

    Funding period: 05/2014- 04/2016
    Grant Title: Role of synthetic analogue (SP) and declustering agent (noscapinoid) in treatment of liver cancer
    Role: PI
    Award amount: $9,500

     

    Completed Research Support

    1. Center for Chronic Diseases of Aging (CCDA) grant

    Funding period: 07/2013- 06/2014
    Grant Title: Role of reprogramming factors in transdifferentiation of hepatocytes to biliary epithelial cells.
    Role: PI
    Award amount: $15,600

    2. University of Pittsburgh, Department of Pathology Post-doctoral Research Training Grant (PPRTP)
    Funding period: 07/2012 – 06/2013
    Grant Title: Role of stem cell/reprogramming factors in transdifferentiation of hepatocytes to biliary epithelial cells.
    Role: PI
    Award amount: $10,000

    3. Society of Toxicology Colgate Palmolive Student Research Training Grant In alternative Methods in Toxicology
    Funding period: 03/2005-02/2006
    Grant Title: Role of Calpastatin in resisting calpain-induced injury in hepatocytes.
    Role: PI
    Award amount: $3,500

  • Awards

    2015: ad-hoc reviewer (ECR) for HBPP study section of CSR, NIH, June 22-23, Washington DC.

    2015: PCOM Research Day student poster, first place. Reprogramming factor Oct4 is crucial for transdifferentiation of hepatocytes to biliary epithelial cells. Mboya Doffou*, George Adams*, Anne Sprain, George Michalopoulos, and Vishakha Bhave.

    2014: American Association of Colleges of Pharmacy, New Investigator Award

    2014: Session chair, “Hepatic Regenerative Medicine: Coping with Injury Via Survival, Proliferation and Stem Cells.” Tuesday April 29, Experimental Biology 2014, San Diego, CA

    2013: Publication (PMID: 23665349) featured in ‘Hot off the Press’ section of American Society of Investigative Pathology (ASIP) newsletter.

    2007: Society of Toxicology Mechanisms Specialty Section Carl Smith Graduate student Award for meritorious research.
    2007: Society of Toxicology, Merck Graduate Travel support.
    2006: Society of Toxicology In Vitro Specialty Section student award, honorable mention.

    2006: American College of Toxicology travel award

    2005: Society of Toxicology Colgate Palmolive Student Research Training Award in Alternative Methods in Toxicology

    2000: Sir Ratan Tata merit scholarship for undergraduate studies in Pharmacy

  • Publications

    1. Liver Regenrtion: Chapter 18, Hepatocyte to Biliary transdifferentiation: To be(come) or not to be(come)? Vishakha Bhave, Elsevier publications, in press, 2015.

    2. Donthamsetty S, Bhave V. S., Mars W., Orr A., Haynes M. M., Wu C., and Michalopoulos G. K. Role of PINCH-Rsu-1 Complex in Regulating Liver size and tumorigenesis, PLOS One, 8(9):e74625, 2013.

    3. Bhave V. S.,, Donthamsetty S., Zhang X., Tan L., Lou J., Bowen B.W., Michalopoulos G.K. Regulation of liver growth by Glypican 3, CD81, Hedgehog, and Hhex. Am J Pathol, 183: 153-159, 2013. This publication (PMID: 23665349) is selected to be featured in ‘Hot off the Press’ section of American Society of Investigative Pathology (ASIP) newsletter, November 2013 issue.

    4. Bhave V. S., Shirish Paranjpe, William C. Bowen, Shashikiran Donthamsetty, Aaron W. Bell, Jaspal S. Khillan, and George K. Michalopoulos. Genes Inducing iPS Phenotype Play a Role in Hepatocyte Survival and Proliferation in vitro and Liver Regeneration in vivo. Hepatology, 54(4):1360-1370, 2011.

    5. Bhave, V. S., Donthamsetty, S., Latendresse, J. R., Cunningham, M., and Mehendale. H. M. Absence of hepatic COX-2 exacerbates sPLA2-mediated progression of hepatotoxicity initiated by acetaminophen. Toxicol. Appl. Pharmacol. 251: 173-180, 2011.

    6. Donthamsetty S, Bhave V. S, Kliment CS, Bowen WC, Mars WM, Bell AW, OrrA, Wu C and Michalopoulos GK Excessive Hepatomegaly of Mice with Hepatocyte-Targeted Elimination of Integrin Linked Kinase Following Treatment by TCPOBOP. Hepatology, 53(2):587-95, 2011.

    7. Chih Wen Lin, Wendy M. Mars Shirish Paranjpe, Shashikiran Donthamsetty, Bhave V. S., Liang I Kang, Anne Orr, William C. Bowen, Aaron W. Bell and George K. Michalopoulos. Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice. Hepatology, 54(2):620-30, 2011.

    8. Donthamsetty S, Bowen WC, Mars WM, Luo JH, Orr A, Bhave V. S., Wu C, Michalopoulos GK. Liver Specific Ablation of Integrin Linked Kinase (ILK) in Mice Results in Enhanced and Prolonged cell proliferation and hepatomegaly after Phenobarbital Administration. Toxicological Sciences, 113(2):358-366, 2010.

    9. Bhave, V. S., Donthamsetty S., Latendresse J. R., Muskhelishvili L, and Mehendale H. M. Secretory phospholipase A2 mediates progression of acute liver injury in the absence of sufficient COX-2. Toxicol. Appl. Pharmacol., 228(2):225-38, 2008.

    10. Bhave, V. S., Donthamsetty S., Latendresse J. R., and Mehendale H. M. Inhibition of COX-2 aggravates secretory phospholipase A2-mediated progression of acute liver injury. Toxicol. Appl. Pharmacol., 228(2):239-46, 2008.

    11. Donthamsetty, S., Bhave, V. S., Mitra, M. S., Latendresse, J. R., and Mehendale HM. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPAR alpha with clofibrate. Toxicol. Appl. Pharmacol., 230(3):327-37, 2008.

    12. Donthamsetty, S., Bhave, V. S., Mitra M. S., Latendresse, J. R., and Mehendale, H. M. Non alcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology, 45(2):391-403, 2007.

    13. Limaye P. B., Bhave V. S., Palkar P. S., Apte U. M., Sawant S. P., Yu S., Latendresse J. R., Reddy J. K., and Mehendale H. M. Upregulation of calpastatin in regenerating and developing livers: Role in resistance against hepatotoxicity. Hepatology, 44(2):379-388, 2006.

  • Memberships

    2013 to present: American Association of Colleges of Pharmacy (AACP)

    2013 to present: Society of Toxicology (SOT)

    2008 to present: American Society of Investigative Pathology (ASIP)

    2010 to 2013: American Association for the Study of Liver Diseases (AASLD)

    2010 to 2012: Trainee member, American Gastroenterological Association (AGA)

    2004-2007: student member, American College of Toxicology (ACT)

    2003-2007: student member, SOT

  • Other

    Dr. Bhave serves as an ad-hoc reviewer for the following:

    • Journal of Pharmacology and Experimental Therapeutics (JPET)
    • Toxicology and Applied Pharmacology (TAAP)
    • BMC cancer
    • Journal of Cell Science
    • American Journal of Pathology (AJP)
    • Toxicological Sciences
    • Liver international
    • Journal of Medical Genomics & Biomarkers
    • Toxicology Letters